

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|---|---------------|-------------------------|------------------------|-------------------|--|
| 09/663,885 | 09/15/2000 | Jeannette Whitcomb | 2793/63122/JPW/JML/CMR | 3908 | |
| 75 | 90 08/15/2002 | | | | |
| Cooper & Dunham LLP | | | EXAMINER | | |
| 1185 Avenue of the Americas New York, NY 10036 | | | PARKIN, JE | PARKIN, JEFFREY S | |
| | | | ART UNIT | PAPER NUMBER | |
| | | | 1648 | C | |
| | | DATE MAILED: 08/15/2002 | | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | |
|--|--------------------------|--|--|--|--|
| n | 09/663,885 | WHITCOMB, JEANNETTE | | | |
| Office Action Summary | Examiner | Art Unit | | | |
| | Jeffrey S. Parkin, Ph.D. | 1648 | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address | | | | | |
| Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>01</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. | | | | | |
| Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status | | | | | |
| 1) Responsive to communication(s) filed on 15 S | September 2000 . | | | | |
| 2a) ☐ This action is FINAL . 2b) ☐ Thi | s action is non-final. | | | | |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | |
| Disposition of Claims | | | | | |
| 4) Claim(s) is/are pending in the application. | | | | | |
| 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | |
| 5) Claim(s) is/are allowed. | | | | | |
| 6) Claim(s) is/are rejected. | | | | | |
| 7) Claim(s) is/are objected to. | | | | | |
| 8)⊠ Claim(s) <u>1-17</u> are subject to restriction and/or election requirement. Application Papers | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | |
| 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | |
| 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner. | | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | |
| 12)☐ The oath or declaration is objected to by the Examiner. | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | |
| 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | |
| a) ☐ All b) ☐ Some * c) ☐ None of: | | | | | |
| 1. Certified copies of the priority documents have been received. | | | | | |
| 2. Certified copies of the priority documents have been received in Application No | | | | | |
| 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | |
| | · | | | | |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). | | | | | |
| a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. | | | | | |
| Attachment(s) | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) | 5) Notice of Informal I | r (PTO-413) Paper No(s) Patent Application (PTO-152) | | | |
| U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office Ac | tion Summary | Part of Paper No. 6 | | | |

 Serial No.: 09/663,885
 Docket No.: 2793/63122

 Applicant: Whitcomb, J.
 Filing Date: 09/15/00

Restriction Requirement

35 U.S.C. § 121

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - a. Group I, claim(s) 1-9, drawn to a method for assessing the effectiveness of non-nucleoside reverse transcriptase (NNRTI) antiviral therapy on a patient by detecting integrase mutations in a patient sample, classified in class 435, subclass 5.

5

10

15

20

25

30

- b. Group II, claim(s) 10-14, drawn to an in vitro screening method for identifying putative HIV antivirals, classified in class 435, subclass 6.
- c. Group III, claim(s) 15-17, drawn to a resistance test vector comprising an HIV-infected patient segment, classified in class 435, subclass 320.1.
- 2. The inventions are distinct, each from the other because of the following reasons:
- 3. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P. § 806.04 and § 808.01). In the instant case, each of the identified groups is directed toward a different scientific objective (i.e., determining a patient prognosis, identifying putative antiviral candidate compounds) that employ structurally and functionally different scientific reagents and assays steps. Therefore, each group is clearly directed toward a different inventive concept.
- 4. Inventions I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P. § 806.04 and § 808.01). In the instant case, the methodology of Group I neither requires

Serial No.: 09/663,885 Applicant: Whitcomb, J.

nor uses the product of Group III. Accordingly, each group is directed toward a different inventive entity.

5. Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the nucleic acid of Group III can be employed in a number of materially different processes such as protein expression assays or nucleic acid-based HIV allelic screening assays.

5

10

15

35

- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and require separate searches, restriction for examination purposes as indicated is proper.
- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. § 1.143).

Correspondence

8. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

Serial No.: 09/663,885 Applicant: Whitcomb, J.

9. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, James Housel or Laurie Scheiner, can be reached at (703) 308-4027 or (703) 308-1122, respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Respectfully,

5

10

Jeffrey S. Parkin, Ph.D.

Patent Examiner Art Unit 1648

14 August, 2002